Cargando…
Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma
Liquid biopsy has been adapted as a diagnostic test for EGFR mutations in patients with advanced or metastatic non-small cell lung cancer (NSCLC). Loop-mediated isothermal amplification (LAMP) has been widely used for the rapid detection of pathogens through DNA amplification. This study investigate...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230792/ https://www.ncbi.nlm.nih.gov/pubmed/35744511 http://dx.doi.org/10.3390/mi13060897 |
_version_ | 1784735155588431872 |
---|---|
author | Saito, Yuichi Matsui, Atsuka Michiyuki, Satoru Morooka, Hiroaki Ibi, Takayuki Yamauchi, Yoshikane Takahashi, Nobumasa Shimizu, Yoshihiko Ikeya, Tomohiko Hoshi, Eishin Sakao, Yukinori Kawamura, Masafumi |
author_facet | Saito, Yuichi Matsui, Atsuka Michiyuki, Satoru Morooka, Hiroaki Ibi, Takayuki Yamauchi, Yoshikane Takahashi, Nobumasa Shimizu, Yoshihiko Ikeya, Tomohiko Hoshi, Eishin Sakao, Yukinori Kawamura, Masafumi |
author_sort | Saito, Yuichi |
collection | PubMed |
description | Liquid biopsy has been adapted as a diagnostic test for EGFR mutations in patients with advanced or metastatic non-small cell lung cancer (NSCLC). Loop-mediated isothermal amplification (LAMP) has been widely used for the rapid detection of pathogens through DNA amplification. This study investigated the efficacy of an EGFR-LAMP assay using plasma samples of patients with resected NSCLC tumors. The EGFR status was investigated using both LAMP and next-generation sequencing (NGS) assays in cases that met the following criteria: (1) pulmonary adenocarcinoma with EGFR mutation detected by the Therascreen EGFR PCR Kit and (2) preoperative plasma samples contained enough DNA for the LAMP and NGS experiments. Among 51 specimens from patients with EGFR-mutated tumors or metastatic lymph nodes, the LAMP assay detected 1 EGFR mutation that was also detected in the NGS assay. However, a plasma sample that demonstrated EGFR wild type in the LAMP assay showed an EGFR mutant status in NGS. The detection rates (1.9% in LAMP and 3.9% in NGS) were very low in both assays, demonstrating a similar performance in detecting EGFR mutations in NSCLC tumors; therefore, it could be a more suitable test for the advanced stage, not the early stage. Notably, the LAMP assay was more time-saving, cost-effective, and straightforward. However, further investigation is required to develop a more sensitive assay. |
format | Online Article Text |
id | pubmed-9230792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92307922022-06-25 Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma Saito, Yuichi Matsui, Atsuka Michiyuki, Satoru Morooka, Hiroaki Ibi, Takayuki Yamauchi, Yoshikane Takahashi, Nobumasa Shimizu, Yoshihiko Ikeya, Tomohiko Hoshi, Eishin Sakao, Yukinori Kawamura, Masafumi Micromachines (Basel) Article Liquid biopsy has been adapted as a diagnostic test for EGFR mutations in patients with advanced or metastatic non-small cell lung cancer (NSCLC). Loop-mediated isothermal amplification (LAMP) has been widely used for the rapid detection of pathogens through DNA amplification. This study investigated the efficacy of an EGFR-LAMP assay using plasma samples of patients with resected NSCLC tumors. The EGFR status was investigated using both LAMP and next-generation sequencing (NGS) assays in cases that met the following criteria: (1) pulmonary adenocarcinoma with EGFR mutation detected by the Therascreen EGFR PCR Kit and (2) preoperative plasma samples contained enough DNA for the LAMP and NGS experiments. Among 51 specimens from patients with EGFR-mutated tumors or metastatic lymph nodes, the LAMP assay detected 1 EGFR mutation that was also detected in the NGS assay. However, a plasma sample that demonstrated EGFR wild type in the LAMP assay showed an EGFR mutant status in NGS. The detection rates (1.9% in LAMP and 3.9% in NGS) were very low in both assays, demonstrating a similar performance in detecting EGFR mutations in NSCLC tumors; therefore, it could be a more suitable test for the advanced stage, not the early stage. Notably, the LAMP assay was more time-saving, cost-effective, and straightforward. However, further investigation is required to develop a more sensitive assay. MDPI 2022-06-06 /pmc/articles/PMC9230792/ /pubmed/35744511 http://dx.doi.org/10.3390/mi13060897 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saito, Yuichi Matsui, Atsuka Michiyuki, Satoru Morooka, Hiroaki Ibi, Takayuki Yamauchi, Yoshikane Takahashi, Nobumasa Shimizu, Yoshihiko Ikeya, Tomohiko Hoshi, Eishin Sakao, Yukinori Kawamura, Masafumi Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma |
title | Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma |
title_full | Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma |
title_fullStr | Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma |
title_full_unstemmed | Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma |
title_short | Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma |
title_sort | loop-mediated isothermal amplification as point-of-care testing for egfr-mutated lung adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230792/ https://www.ncbi.nlm.nih.gov/pubmed/35744511 http://dx.doi.org/10.3390/mi13060897 |
work_keys_str_mv | AT saitoyuichi loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT matsuiatsuka loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT michiyukisatoru loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT morookahiroaki loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT ibitakayuki loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT yamauchiyoshikane loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT takahashinobumasa loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT shimizuyoshihiko loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT ikeyatomohiko loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT hoshieishin loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT sakaoyukinori loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma AT kawamuramasafumi loopmediatedisothermalamplificationaspointofcaretestingforegfrmutatedlungadenocarcinoma |